Reshaping the HIV treatment and prevention landscape
Zejula: best-in-class and only PARP inhibitor approved
for all 1L ovarian cancer patients
Positioned to benefit broadest population
Ovarian Cancer Biomarker Subgroups
Opportunity to drive market growth
and reduce use of 'watch and wait'
gsk
HRd1
HRp2
BRCAM²
25%
50%
BRCAwt²
25%
HRd1
1st PARPi to
demonstrate
benefit in 1L OC3
regardless of
biomarker status
% of patients
5%
6%
1LM Eligible US Patients4
15%
19%
11%
30%
85%
65%
58%
2017-2018
PARPIS
enter 2L OC market
2018-2019
First PARPi
available in
BRCAM 1LM
-
2019 2020
PRIMA approval
expands PARPi in
1LM to all comers
Watch & Wait
Bevacizumab
PARPi
1. The Cancer Genome Atlas Research Network. Nature. 2011;474(7353):609–615.
2. Pennington KP, Walsh T, Harrell MI, et al. Clin Cancer Res. 2014;20(3):764–775.
3. Refers to ovarian cancer patients who responded to 1L chemotherapy
4. Flatiron, July 2020
95View entire presentation